MX2016001096A - Sales de dasatinib en forma amorfa. - Google Patents

Sales de dasatinib en forma amorfa.

Info

Publication number
MX2016001096A
MX2016001096A MX2016001096A MX2016001096A MX2016001096A MX 2016001096 A MX2016001096 A MX 2016001096A MX 2016001096 A MX2016001096 A MX 2016001096A MX 2016001096 A MX2016001096 A MX 2016001096A MX 2016001096 A MX2016001096 A MX 2016001096A
Authority
MX
Mexico
Prior art keywords
salts
dasatinib
amorphous form
relates
salt
Prior art date
Application number
MX2016001096A
Other languages
English (en)
Inventor
Martin Szelagiewicz
Fritz Blatter
Tiziana Chiodo
Andreas Hafner
Tobias Hintermann
Beate Salvador
Bernd Siebenhaar
Marcus Vossen
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of MX2016001096A publication Critical patent/MX2016001096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom

Abstract

La presente invención principalmente se refiere a sales de Dasatinib, en donde las sales están en forma amorfa. Las sales descritas en este documento comprenden un catión de un compuesto de fórmula 1 (ver Fórmula) y un anión de un segundo compuesto seleccionado del grupo que consiste en ácido glutárico, ácido nicotínico y sacarina. La invención se refiere en forma adicional a composiciones farmacéuticas que comprenden dicha sal. Además, la invención se refiere a procesos para preparar dichas sales. La invención se refiere a varios aspectos del uso de dicha sal o composición farmacéutica para tratar una enfermedad.
MX2016001096A 2013-07-25 2014-07-22 Sales de dasatinib en forma amorfa. MX2016001096A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13178015 2013-07-25
PCT/EP2014/065674 WO2015011119A2 (en) 2013-07-25 2014-07-22 Salts of dasatinib in amorphous form

Publications (1)

Publication Number Publication Date
MX2016001096A true MX2016001096A (es) 2016-04-25

Family

ID=48832837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001096A MX2016001096A (es) 2013-07-25 2014-07-22 Sales de dasatinib en forma amorfa.

Country Status (10)

Country Link
US (1) US9884857B2 (es)
EP (1) EP3024831A2 (es)
JP (1) JP6370377B2 (es)
KR (1) KR101831535B1 (es)
CN (1) CN105377842A (es)
AU (1) AU2014295143B9 (es)
CA (1) CA2917209A1 (es)
MX (1) MX2016001096A (es)
RU (1) RU2655435C2 (es)
WO (1) WO2015011119A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3166932B1 (en) 2014-07-08 2018-06-20 BASF Agro B.V. Process for the preparation of substituted oxiranes and triazoles
CN107635982A (zh) 2015-05-08 2018-01-26 巴斯夫农业公司 制备萜品油烯环氧化物的方法
WO2016180614A1 (en) 2015-05-08 2016-11-17 Basf Se A process for the preparation of limonene-4-ol
ES2877169T3 (es) 2016-06-15 2021-11-16 Basf Agro Bv Procedimiento para la epoxidación de un alqueno tetrasustituido
ES2833202T3 (es) 2016-06-15 2021-06-14 Basf Agro Bv Procedimiento para la epoxidación de un alqueno tetrasustituido
CN107501305B (zh) * 2017-09-26 2019-04-05 玉林师范学院 一种达沙替尼-铜(ii)配合物及其合成方法和应用
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
CA3102381A1 (en) 2018-06-15 2019-12-19 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
WO2021150981A1 (en) 2020-01-24 2021-07-29 Nanocopoeia, Llc Amorphous solid dispersions of dasatinib and uses thereof
JP2023520021A (ja) * 2020-03-30 2023-05-15 アイジーアイエー ファーマシューティカルズ インコーポレイテッド チロシンキナーゼ阻害剤の小児用製剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
PL215901B1 (pl) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
JP4906233B2 (ja) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
EP1937270A1 (en) 2005-09-21 2008-07-02 Brystol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
KR20120033357A (ko) 2007-10-23 2012-04-06 테바 파마슈티컬 인더스트리즈 리미티드 다사티닙 다형체 및 이의 제조 방법
WO2010062715A2 (en) 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010067374A2 (en) 2008-12-08 2010-06-17 Hetero Research Foundation Polymorphs of dasatinib
CZ20098A3 (cs) * 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
CN102030745B (zh) 2010-11-26 2012-05-09 江苏先声药物研究有限公司 Dasatinib溶剂合物及其制备方法
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
CN102898424A (zh) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 达沙替尼新的多晶型物及其制备方法
US20140205641A1 (en) 2011-08-30 2014-07-24 Basf Se Co-Crystals of Cyprodinil and Dithianon
CN102429880B (zh) * 2011-11-29 2014-10-15 上海创诺制药有限公司 一种达沙替尼片
US9199997B2 (en) 2011-11-29 2015-12-01 Ono Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
US8796481B2 (en) 2011-12-30 2014-08-05 Basf Se Crystalline solvate and non-solvated forms of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo [d,f] [1,3,2]-dioxaphosphepine
US9340536B2 (en) 2012-06-15 2016-05-17 Basf Se Multicomponent crystals comprising dasatinib and selected co-crystal formers
CA2877030A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
ES2598168T3 (es) 2012-08-06 2017-01-25 Basf Se Sistema cristalino de múltiples componentes que comprende deferasirox e isonicotinamida y procedimiento para la preparación del mismo
BR112015008552A2 (pt) 2012-10-19 2017-07-04 Basf Se material cristalino, composição farmacêutica, e, processo para a preparação de um material cristalino
KR20150095749A (ko) 2012-12-20 2015-08-21 바스프 에스이 그래핀 소재의 에지 할로겐화
EP2964033A1 (en) 2013-03-07 2016-01-13 Basf Se Co-crystals of pyrimethanil and selected dithiine tetracarboximide

Also Published As

Publication number Publication date
WO2015011119A2 (en) 2015-01-29
US9884857B2 (en) 2018-02-06
EP3024831A2 (en) 2016-06-01
AU2014295143A1 (en) 2016-02-11
WO2015011119A3 (en) 2015-05-28
KR20160025573A (ko) 2016-03-08
CN105377842A (zh) 2016-03-02
JP2016525528A (ja) 2016-08-25
RU2016106124A (ru) 2017-08-30
AU2014295143B2 (en) 2017-03-16
KR101831535B1 (ko) 2018-02-22
US20160168142A1 (en) 2016-06-16
JP6370377B2 (ja) 2018-08-08
RU2655435C2 (ru) 2018-05-29
AU2014295143B9 (en) 2017-03-23
CA2917209A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
MX2016001096A (es) Sales de dasatinib en forma amorfa.
MX2016001095A (es) Sales de dasatinib en forma cristalina.
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201492092A1 (ru) Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
BR112013020996A8 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
PH12018501644A1 (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
EA201792072A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
WO2014153203A3 (en) Alkyl-amine harmine derivatives for promoting bone growth
NZ738836A (en) Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
PH12019500822A1 (en) Crystalline forms of eravacycline
MX337721B (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
MX359069B (es) Sal y formas cristalinas de inhibidor de quinasa tipo polo-4.
MX362858B (es) Proceso para la preparacion de pemetrexed y sal de lisina del mismo.
MA39715A (fr) Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
UA111334C2 (uk) Дельта-кристалічна форма аргінінової солі периндроприлу, спосіб її одержання і фармацевтична композиція, яка її містить
EA201591704A1 (ru) Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии